Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial GuidanceBusiness Wire • 01/10/22
Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/05/22
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Tom McCourt on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/06/21
Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development UpdateBusiness Wire • 11/04/21
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.Business Wire • 11/04/21
More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021Business Wire • 10/25/21
Ironwood Pharmaceuticals to Participate in Upcoming September Investor ConferencesBusiness Wire • 09/02/21
Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) LabelBusiness Wire • 08/26/21
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Tom McCourt on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/08/21
Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year GuidanceBusiness Wire • 08/05/21
Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 07/29/21